🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03031210
Recruiting Phase 2/3

Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.

NCT03031210 · tracked via the Priya Life Science Canada tracker
Phase
Phase 2/3
Started
2017-06-11
Last updated
2025-05-14

Condition(s) studied

Community-acquired Pneumonia

Investigational drug(s) / intervention(s)

Amoxicillin →

Amoxicillin: (90 mg/kg/day) twice daily

Study summary

The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).

Eligibility

Sex
ALL
Min age
3 Months
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * All patients 3 months to 18 years of age attending the pediatric ED and diagnosed with a non-severe pneumonia, will be considered for enrolment. More precisely, the following inclusion criteria will be required: 1. Presence of respiratory symptoms (cough and/or dyspnea) 2. Presence of signs of pneumonia (tachypnea, abnormal breath sounds, crackles) 3. Presence of fever 4. Positive chest radiography as interpreted by the treating physician Exclusion Criteria: * Any danger signs associated with pneumonia (severe indrawing, shock or severe dehydration, empyema, important pleural effusion, pulmonary abcess or pneumatocoele) * History of anaphylactic or allergic reaction to penicillin or amoxicillin according to the treating physician. * History of a serious nonimmunoglobulin E-mediated reactions (eg, Stevens-Johnson syndrome or toxic epidermal necrolysis) attributed to amoxicilin. * Caregiver unable to provide consent (language barrier or lack of caregiver presence) * Underlying unstable chronic illness (ie. cystic fibrosis, immune suppression, active tuberculosis, bronchiectasis or active pulmonary malignancies) * Persistent/chronic pneumonia syndromes (with symptoms for \>2 weeks), suspected by the physician to be caused by atypical pathogens, hospital- acquired pneumonia (been hospitalized within 2 weeks prior to enrolment), aspiration pneumonia or recurrent pneumonias. * Any history of receiving amoxicillin within the past month * Need hospitalisation for any other reasons (ie. persistent vomiting, severe life-threatening infection such as septicaemia or meningitis requiring intravenous antimicrobial agents) * Previous participation in study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Sainte-Justine Montreal Quebec Recruiting

On this site

📄 Amoxil (amoxicillin) drug profile →

More St. Justine's Hospital trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03031210 on ClinicalTrials.gov ↗ ← All trials in Canada